Salvatore Cuzzocrea1,2, Emanuela Mazzon3,4, Emanuela Esposito5, Carmelo Muià3, Maha Abdelrahman6, Rosanna Di Paola3,4, Concetta Crisafulli3, Placido Bramanti4, Christoph Thiemermann6. 1. Department of Clinical and Experimental Medicine and Pharmacology, School of Medicine, University of Messina, Messina, Italy. salvator@unime.it. 2. IRCCS Centro Neurolesi Bonino-Pulejo, Messina, Italy. salvator@unime.it. 3. Department of Clinical and Experimental Medicine and Pharmacology, School of Medicine, University of Messina, Messina, Italy. 4. IRCCS Centro Neurolesi Bonino-Pulejo, Messina, Italy. 5. Department of Experimental Pharmacology, University of Naples Federico II, Naples, Italy. 6. William Harvey Research Institute, Centre for Experimental Medicine, Nephrology and Critical Care, St. Bartholomew's, and Royal London School of Medicine and Dentistry, London, UK.
Abstract
OBJECTIVE: This study investigated the effects of TDZD-8, a potent and selective GSK-3beta inhibitor, on tissue injury caused by ischaemia/reperfusion (I/R) of the gut. DESIGN AND SETTING: Animal study in the Department of Clinical and Experimental Medicine and Pharmacology, School of Medicine, University of Messina, Italy. SUBJECTS: Splanchnic artery occlusion (SAO) shocked rats. INTERVENTIONS: I/R injury of the intestine was caused by clamping both the superior mesenteric artery and the coeliac trunk for 45 min followed by release of the clamp allowing reperfusion for 1 or 6 h. This procedure results in SAO shock. MEASUREMENTS AND RESULTS: Only 10% of the SAO animals survived the entire 6 h reperfusion period. In a separate set of experiments after 60 min of reperfusion animals were killed for histological examination and biochemical studies. Administration of TDZD-8 (1 mg/kg i.v.) 5 min prior to the reperfusion significantly reduced the (a) fall in mean arterial blood pressure, (b) mortality rate, (c) infiltration of the reperfused intestine with polymorphonuclear neutrophils (MPO activity), (d) production of pro-inflammatory cytokines (TNF-alpha and IL-1 beta and (e) histological evidence of gut injury. Administration of TDZD-8 also markedly reduced the immunoreactivity of nitrotyrosine formation and the expression of ICAM-1 and P-selectin during reperfusion. CONCLUSIONS: Based on these findings we propose that TDZD-8 would be useful in the treatment of various ischaemia and reperfusion diseases.
OBJECTIVE: This study investigated the effects of TDZD-8, a potent and selective GSK-3beta inhibitor, on tissue injury caused by ischaemia/reperfusion (I/R) of the gut. DESIGN AND SETTING: Animal study in the Department of Clinical and Experimental Medicine and Pharmacology, School of Medicine, University of Messina, Italy. SUBJECTS:Splanchnic artery occlusion (SAO) shocked rats. INTERVENTIONS: I/R injury of the intestine was caused by clamping both the superior mesenteric artery and the coeliac trunk for 45 min followed by release of the clamp allowing reperfusion for 1 or 6 h. This procedure results in SAO shock. MEASUREMENTS AND RESULTS: Only 10% of the SAO animals survived the entire 6 h reperfusion period. In a separate set of experiments after 60 min of reperfusion animals were killed for histological examination and biochemical studies. Administration of TDZD-8 (1 mg/kg i.v.) 5 min prior to the reperfusion significantly reduced the (a) fall in mean arterial blood pressure, (b) mortality rate, (c) infiltration of the reperfused intestine with polymorphonuclear neutrophils (MPO activity), (d) production of pro-inflammatory cytokines (TNF-alpha and IL-1 beta and (e) histological evidence of gut injury. Administration of TDZD-8 also markedly reduced the immunoreactivity of nitrotyrosine formation and the expression of ICAM-1 and P-selectin during reperfusion. CONCLUSIONS: Based on these findings we propose that TDZD-8 would be useful in the treatment of various ischaemia and reperfusion diseases.
Authors: S Cuzzocrea; T P Misko; G Costantino; E Mazzon; A Micali; A P Caputi; H Macarthur; D Salvemini Journal: FASEB J Date: 2000-06 Impact factor: 5.191
Authors: S Cuzzocrea; C Crisafulli; E Mazzon; E Esposito; C Muià; M Abdelrahman; R Di Paola; C Thiemermann Journal: Br J Pharmacol Date: 2006-10-03 Impact factor: 8.739
Authors: Laura Dugo; Marika Collin; David A Allen; Nimesh S A Patel; Inge Bauer; Eero M A Mervaala; Marjut Louhelainen; Simon J Foster; Muhammad M Yaqoob; Christoph Thiemermann Journal: Crit Care Med Date: 2005-09 Impact factor: 7.598
Authors: Kayode K Ojo; Tracy L Arakaki; Alberto J Napuli; Krishna K Inampudi; Katelyn R Keyloun; Li Zhang; Wim G J Hol; Christophe L M J Verlinde; Ethan A Merritt; Wesley C Van Voorhis Journal: Mol Biochem Parasitol Date: 2010-12-30 Impact factor: 1.759
Authors: Michael Maes; Zdenĕk Fišar; Miguel Medina; Giovanni Scapagnini; Gabriel Nowak; Michael Berk Journal: Inflammopharmacology Date: 2012-01-24 Impact factor: 4.473
Authors: Hoeke A Baarsma; Lilian H J M Engelbertink; Lonneke J van Hees; Mark H Menzen; Herman Meurs; Wim Timens; Dirkje S Postma; Huib A M Kerstjens; Reinoud Gosens Journal: Br J Pharmacol Date: 2013-06 Impact factor: 8.739
Authors: Rosanna Di Paola; Marta Menegazzi; Emanuela Mazzon; Tiziana Genovese; Concetta Crisafulli; Martina Dal Bosco; Zhenzhen Zou; Hisanori Suzuki; Salvatore Cuzzocrea Journal: Intensive Care Med Date: 2008-10-25 Impact factor: 17.440
Authors: Zhiyong Wang; Andrea Havasi; Jonathan Gall; Ramon Bonegio; Zhijian Li; Haiping Mao; John H Schwartz; Steven C Borkan Journal: J Am Soc Nephrol Date: 2010-01-21 Impact factor: 10.121
Authors: Jerry J Flores; Yang Zhang; Damon W Klebe; Tim Lekic; Weiling Fu; John H Zhang Journal: Expert Opin Pharmacother Date: 2014-02-04 Impact factor: 3.889